Showing 151–175 of 185 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Ahmed M, Farris E, Swanson RV, Das S, Yang Y, et al.
…o affect other sites (extrapulmonary TB). The only licensed vaccine Mycobacterium bovis bacillus Calmette-Guerin (BCG) protects infants and young children but exhibits variable efficacy in protecting against adult pulmonary TB. Poor compliance and prolonged treatment regimens ass…
Enriquez AB, Izzo A, Miller SM, Stewart EL, Mahon RN, et al.
…f death worldwide due to a single infectious disease agent. BCG, the only licensed vaccine against TB, offers limited protection against pulmonary disease in children and adults. TB vaccine research has recently been reinvigorated by new data suggesting alternative administration…
Sethi G, Varghese RP, Lakra AK, Nayak SS, Krishna R, et al.
…the situation more concerning. Currently, the only licensed vaccine BCG (Bacillus Calmette-Guérin) is ineffective in preventing adult pulmonary tuberculosis prophylaxis and latent tuberculosis re-activation. Therefore, there is a pressing need to find novel and safe vaccines that…
Schrager LK, Vekemens J, Drager N, Lewinsohn DM, Olesen OF
…imelines to control the spread of the disease require a new vaccine capable of preventing tuberculosis, particularly in adolescents and adults. The spread of strains resistant to multiple drugs adds additional urgency to the vaccine development effort yet attempts to develop new …
Lubyayi L, Mawa PA, Nabakooza G, Nakibuule M, Tushabe JV, et al.
Background: BCG has low efficacy in tropical countries. We hypothesized that maternal latent Mycobacterium tuberculosis (M.tb) infection (LTBI) results in fetal tolerance to mycobacterial antigens and impaired responses to BCG immunization. Methods: We enrolled 132 LTBI-positive …
Watt J, Liu J, Liu J
…B and 1.45 million deaths in 2018. Bacille Calmette-Guérin (BCG) remains the only approved vaccine for Mycobacterium tuberculosis ( M. tb , causative agent of TB), however clinical studies have shown BCG has variable effectiveness ranging from 0-80% in adults. With 1.7 billion pe…
Jeyanathan M, Xing Z
…obal health concerns. There has been a lack of an effective vaccine strategy. The Bacillus Calmette-Guerin (BCG), the only licensed vaccine against TB, is not effective against adult pulmonary TB, the highly contagious form of TB. In the past two decades or so, many novel TB vacc…
Runlin Wang, Xiaochun Wang, Lingyun Kong, Qishan Sun, Jiagao Wu, et al.
…terium tuberculosis (M. tb). Bacillus Calmette-Guérin (BCG) is currently the only approved vaccine for TB prevention; however, its protective efficacy against tuberculosis in adults is limited. To overcome the limitations of BCG, recombinant plasmids were constructed and exp…
Scriba TJ, Netea MG, Ginsberg AM
…loyment of standard drug regimens, modern diagnostics and a vaccine (bacille Calmette Guerin, BCG), the global tuberculosis epidemic is inadequately controlled. Novel, effective vaccine(s) are a crucial element of the World Health Organization End TB Strategy. TB vaccine research…
Chugh S, Bahal RK, Dhiman R, Singh R
…he risk of TB is immunization with bacilli Calmette-Guerin (BCG). Although BCG has been widely used to protect against TB, reports show that BCG confers highly variable efficacy (0-80%) against adult pulmonary TB. Unwavering efforts have been made over the past 20 years to develo…
Dongdong Zhang, Donghui Wang, Shuo Jiang, Yue Wan, Yukun Zhao, et al.
…at affects people worldwide. Bacillus Calmette-Guérin (BCG), the only approved TB vaccine, has been shown to have highly variable protective efficacy in different populations and is ineffective at protecting adults. Therefore, the development of more effective TB vaccines is…
Li J, Zhao A, Tang J, Wang G, Shi Y, et al.
Bacillus Calmette-Guérin (BCG) has been in use for nearly 100 years and is the only licensed TB vaccine. While BCG provides protection against disseminated TB in infants, its protection against adult pulmonary tuberculosis (PTB) is variable. To achieve the ambitious goal of eradi…
Larson EC, Ellis-Connell AL, Rodgers MA, Gubernat AK, Gleim JL, et al.
…ficiency virus (HIV). Intra-dermal Bacille Calmette-Guérin (BCG) delivery is the only licensed vaccine against tuberculosis; however, it offers little protection from pulmonary tuberculosis in adults and is contraindicated in people living with HIV. Intravenous BCG confers protec…
Yang Y, Chen YZ, Xia T
…omplex (MTBC). For a century, the Bacillus Calmette-Guérin (BCG) vaccine has been the primary preventive measure against TB. While it effectively protects against extrapulmonary forms of pediatric TB, it lacks consistent efficacy in providing protection against pulmonary TB in ad…
Bull NC, Kaveh DA, Garcia-Pelayo MC, Stylianou E, McShane H, et al.
…use of human mortality from an infectious disease. The only vaccine currently available, bacille Calmette-Guérin (BCG), demonstrates some protection against disseminated disease in childhood but very variable efficacy against pulmonary disease in adults. A greater understanding o…
Abil OZ, Liu S, Yeh YW, Wu Y, Sen Chaudhuri A, et al.
…the top three causes of death. Currently, the only licensed vaccine against TB is the bacillus Calmette-Guerin (BCG), which lacks efficacy in preventing and controlling pulmonary TB in adults. We aimed to evaluate a nasal TB vaccine formulation composed of the Mtb-specific vaccin…
Carlos Martín, Jesús Gonzalo-Asensio, Nacho Aguiló, Ainhoa Arbués
…d ultimately elimination - will remain unachieved without a vaccine capable of preventing pulmonary disease and transmission. Bacille Calmette-Guérin (BCG), a live attenuated vaccine derived from Mycobacterium bovis and the only licensed TB vaccine, has been widely implement…
Qian C, Fan X, Wang R, Cao B, Yu J, et al.
…ad use of the Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine, the primary factor for the TB pandemic and deaths is adult TB, which mainly result from endogenous reactivation of latent Mycobacterium tuberculosis (MTB) infection. Improved new TB vaccines with eligible s…
Szachniewicz MM, Neustrup MA, van den Eeden SJF, van Meijgaarden KE, Franken KLMC, et al.
…ew cases and 1.3 million deaths annually. The only existing vaccine, Mycobacterium Bovis Bacillus Calmette-Guérin (BCG), provides highly variable and inadequate protection in adults and adolescents. This study explores newly developed subunit tuberculosis vaccines that use a mult…
Clark RA, Sumner T, Weerasuriya CK, Bakker R, Scriba TJ, et al.
…upcoming trial may provide further evidence that adolescent/adult-targeted BCG revaccination prevents sustained Mycobacterium tuberculosis infection, but its public health value depends on its impact on overall tuberculosis morbidity and mortality, which will remain unknown. Usin…
Jessica R Jarvela, Julie G Burel, Michelle Moyer, Bonnie A Thiel, Htin Aung, et al.
…ldwide public health threat, in part because of the limited efficacy of current BCG vaccination. Respiratory infection with Mycobacterium tuberculosis (Mtb) is most often followed by the development of protective immunity that contains the pathogen, resulting in latent tuberculos…
Jin Yin, Min Yu
…y and are less affected by non-tuberculous mycobacteria and BCG vaccine. However, the efficacy of QFT-Plus and C-TST in suspected tuberculosis remain unclear. We compared the performance of the QFT-Plus with the C-TST in auxiliary diagnosing tuberculosis in individuals with suspe…
M S Cinar, T M Adams, A Ozdilek, F Y Avci
Nucleic acid vaccines, including mRNA platforms, represent a transformative approach by inducing adaptive immunity against-expressed antigens. Tuberculosis (TB), caused by(), remains a leading global health threat. The only licensed TB vaccine, Bacillus Calmette-Guérin (BCG)…
Yadav J, Phogat S, Chaudhary D, Jaiwal R, Jaiwal PK
Objectives The only approved vaccine, Bacillus Calmette Guérin (BCG) used in global tuberculosis (TB) immunization programmes has been very effective in childhood TB but not in adult pulmonary and latent TB. Moreover, the emergence of multi-drug resistance-TB cases demands either…
Pere-Joan Cardona
Tuberculosis (TB) vaccine development is hindered by the absence of validated correlates of protection, the low proportion of infected individuals who progress to disease, and the pervasive impact of reinfection in endemic settings. Although several candidates have advanced clini…